Industry Satellite Symposia

The American Society for Radiation Oncology (ASTRO) has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposium. The symposia constitute the content and views of the provider and is not part of the official ASTRO Annual Meeting program.

---

Sunday, October 23, 2022

6:00 p.m. – 8:00 p.m. | Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors

Location: Grand Hyatt San Antonio River Walk, Texas Ballroom Salon A/B
600 E. Market Street
San Antonio, TX 78205

6:00 p.m. – 6:30 p.m.: Registration and Dinner
6:30 p.m. – 8:00 p.m.: Symposium

For more information or to register for our live symposium in San Antonio, please visit peerview.com/SanAntonio22-Live.

Not going to San Antonio? Register for the live virtual symposium instead! For more information or to register, please visit peerview.com/SanAntonio22-Live.

Accreditation:
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

CME Credits: PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, neuro-oncologists and other health care professionals involved in the care of patients with solid tumors.

Learning Objectives:
Upon completion of this activity, participants should be better able to:

• Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM).
• Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal and gynecologic cancers.
• Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM and other solid tumors.
• Employ evidence and team-based strategies to mitigate and manage AEs associated with novel LRTs (e.g.,TTFields) in patients with solid tumors.

Agenda: 

• 6:00 p.m. CT: Registration and Dinner
• 6:30 p.m.CT: In-Person and Virtual Symposium
• Introduction: The Evolving Era of Cancer Treatment
• Seminar and Practicum Sessions
  • Building on a Solid Foundation: TTFieldsin GBM
  • Multimodal Treatment of MPM and Other Thoracic Cancers: Gaining Ground With TTFields
• Racing Toward the Future: Can Innovative Multimodal Approaches Extend Survival in Other Solid Tumors?
• Audience Q&A
• 8:00 p.m. CT: Adjourn

Chair and Presenter: Erik P. Sulman, MD, PhD, NYU Grossman School of Medicine, Laura and Isaac Perlmutter Cancer Center, New York

Presenters:

• Zachary D. Horne, MD, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania
• Rupesh Kotecha, MD, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida

This activity is supported through an educational grant from Novocure, Inc.

---

Monday, October 24, 2022

5:30 p.m. - 7:00 p.m. | Innovations in the Treatment of LA SCCHN
Enhancing Antitumor Activity through IAP Antagonism

Location: Grand Hyatt San Antonio, Lone Star Salon A/B
600 E. Market Street
San Antonio, TX 78205

5:30 p.m. – 6:00 p.m.: Registration and Dinner
6:00 p.m. – 7:00 p.m.: Symposium

For more information or to register for our live symposium in San Antonio, please visit www.reachmd.com/scchn.

Not going to San Antonio? Tune in to our live web broadcast instead! For more information or to register for our live web broadcast, please visit www.reachmd.com/scchn-virtual.

 

Accreditation: In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Provider: AGILE - Academy for Global Interprofessional Learning and Education - designs, develops and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps health care professionals improve competence, performance and patient outcomes.

CME Credits: Global Learning Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target audience: Medical oncologists, pathologists, radiation oncologists and other health care professionals treating patients with head and neck cancers.

Learning Objectives:

1. Describe factors that contribute to patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) experiencing disease progression/recurrence.
2. Assess the risks, benefits and limitations of agents currently available as treatment options for the management of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
3. Differentiate the mechanisms of action of agents currently being investigated for the treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) from those of currently available treatment options.
4. Assess the therapeutic potential of agents being investigated for the management of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

 

Agenda Topics:
*Subject to change.

Faculty:

1. Barbara Burtness, MD
2. Kevin Harrington, MD
3. Ari Rosenberg, MD

This activity is supported by an independent educational grant from health care business of Merck KGaA, Darmstadt, Germany.

Monday, October 24, 2022

6:30 p.m. - 8:30 p.m. | Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal is Cure?

This ISS will be held virtually only.

Tune in to our live web broadcast! For more information or to register for our live web broadcast, please visit www.Gotoper.com/MXFnsclc. 

Accreditation: Physicians' Education Resourse, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

CME Credits: Physicians' Education Resourse, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Target audience: This educational program is directed toward medical, surgical and radiation oncologists who treat or manage patients with non-small cell lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of non-small cell lung cancer are also invited to participate.
 
Learning Objectives: Upon completion of this activity, participants will be able to:

1. Discuss the rationale for applying immunotherapeutic strategies to early-stage and locally advanced NSCLC settings, as well as key considerations in multidisciplinary coordination between thoracic surgeons, medical oncologists, and radiation oncologists.
2. Assess recent data and emerging trends utilizing immune checkpoint inhibitor-based strategies for the management of patients with unresectable stage III NSCLC.
3. Devise personalized care strategies to integrate evidence with evolving immunotherapy-based approaches to manage patients with resectable stage I-III NSCLC.
4. Create interdisciplinary care strategies for the management of stage I-III NSCLC that include methods to monitor for, identify, and mitigate the impact of irAEs.

Agenda Topics: 
 

Time	Topic
6:30 p.m.	Welcome, Introductions, and Pre-session Survey
6:40 p.m.	Assessing the Rapidly Evolving Role of Immunotherapy in Stages I-III NSCLC
6:55 p.m.	Medical Crossfire® Panel 1: Utilizing Immunotherapeutic Approaches in Adjuvant and Neoadjuvant Settings
7:35 p.m.	Medical Crossfire® Panel 2: Evolving Strategies for Immunotherapy-Based Regimens in Unresectable Stage III NSCLC
8:15 p.m.	Audience Q&A
8:25 p.m.	Post-session Survey
8:30 p.m.	Adjourn

Chair: Heather A. Wakelee, MD, FASCO, Professor of Medicine and Chief of the Division of Oncology, Stanford University School of Medicine, Deputy Director, Stanford Cancer Institute, Stanford, CA

Faculty:

1. Lyudmila Bazhenova, MD, Clinical Professor of Medicine Director, Hematology Oncology Training Program Lung Cancer Team Leader University of California, San Diego Moores Cancer Center La Jolla, California
2. Brendon M. Stiles, MD, Chief, Thoracic Surgery and Surgical Oncology, Montefiore Health System, Associate Director Surgical Services, Montefiore Einstein Cancer Center Bronx, NY Professor, Cardiothoracic and Vascular Surgery, Albert Einstein College of Medicine, Bronx, New York
3. Kristin Higgins, MD, Associate Professor, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta

This activity is supported by an independent educational grant from AstraZeneca.